Microvascular Angina Could Have Risk Gradients

This study recently published in JACC paves the way to identifying higher risk patients among those with no epicardial coronary artery disease (CAD) that present angina symptoms. 

La angina microvascular podría tener gradientes de riesgo

Evidence of coronary spasm and increased microcirculation resistance in patients with angina (but with no epicardial obstructive CAD) is associated with increased risk of adverse cardiac events. 

AT nearly two-year follow-up, patients with vasospastic angina and elevated microcirculation resistance rates (IMR) had 6 times more chances of events compared against patients with no vasospastic angina and normal IMR, despite the fact that they all had the same symptoms (HR 6.23; CI 95% 1.21 to 118.48).

Cardiology has always focused on obstructive CAD, and has developed many tools with great efficacy, even in hard end points such as mortality. Among others, there are the stents, CABG, statins, and antiplatelet drugs. But when it comes to patients with no epicardial CAD, we do not have that many tools, not even information. 


Read also: AHA 2019 | ISCHEMIA: The Invasive Approach (PCI or Surgery) Results Similar to Optimal Medical Treatment.


Obstructive CAD predominantly affects men; instead, microvascular dysfunction predominantly affects women. 

Microvascular dysfunction has been typically defined by IMR >25, but this study shows there is a cutoff value of 18 that identifies patients with worse prognosis. 

IMR measurements are not available in the daily practice in many centers and the “normal” value remains controversial, but what we should learn from this study is that roughly three quarters of patients with angina and epicardial CAD with no lesions have microvascular dysfunction. 

When the coronary angiography does not show lesions, we tend to think of mistakes in prior tests, or that the patient has a psychiatric problem. Now, little by little, we start to see there is a whole clinical syndrome beyond obstructive CAD. 

Original Title: Coronary functional abnormalities in patients with angina and nonobstructive coronary artery disease.

Reference: Suda A et al. J Am Coll Cardiol. 2019;74:2350-2360.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...